OBX (Obsidian Therapeutics) Total Stockholders Equity: $-266.04 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
8 GF Score
Price $27.50
View Full Analysis

What is Obsidian Therapeutics Total Stockholders Equity?

Obsidian Therapeutics OBX -1.79% 8 Total Stockholders Equity is $-266.04 Mil as of Dec. 2025. GuruFocus rates OBX with a GF Score™ of 8/100.

Obsidian Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-266.04 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Obsidian Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Obsidian Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2025 was -0.02.

Obsidian Therapeutics  (NAS:OBX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Obsidian Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-266.037-0)/0
=N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Obsidian Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.059 + 1.224) / -266.037
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics Total Stockholders Equity Related Terms

Obsidian Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics Total Stockholders Equity Chart

Obsidian Therapeutics Annual Data
Trend Dec24 Dec25
Total Stockholders Equity
-174.43 -266.04

Obsidian Therapeutics Semi-Annual Data
Dec24 Dec25
Total Stockholders Equity -174.43 -266.04
OBX
8GF Score
Obsidian Therapeutics Inc OBX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-266.04 Mil mean?
Obsidian Therapeutics (OBX) has a Total Stockholders Equity of $-266.04 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Obsidian Therapeutics and its competitors.
Is Obsidian Therapeutics' Total Stockholders Equity too high?
Obsidian Therapeutics' current Total Stockholders Equity is $-266.04 Mil. Overall, Obsidian Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' Total Stockholders Equity compare to ?
Obsidian Therapeutics' Total Stockholders Equity of $-266.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Obsidian Therapeutics and its competitors. Obsidian Therapeutics's current Total Stockholders Equity is $-266.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current Total Stockholders Equity of $-266.04 Mil. The current Total Stockholders Equity is $-266.04 Mil. Obsidian Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current Total Stockholders Equity is $-266.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Obsidian Therapeutics Business Description

Comparable Companies
Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score

Get the complete analysis for OBX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.50
Price